Phaseline

Targets › TGFBR1

TGFBR1 (TGF-beta receptor type-1): drug programs, companies and trials

6 programs from 6 companies in 7 trials: 3 Phase 1, 3 Phase 2, 1 Phase 3; Oncology; next expected readout Dec 2026.

Transmembrane serine/threonine kinase forming with the TGF-beta type II serine/threonine kinase receptor, TGFBR2, the non-promiscuous receptor for the TGF-beta cytokines TGFB1, TGFB2 and TGFB3. Transduces the TGFB1, TGFB2 and TGFB3 signal from the cell surface to the cytoplasm and is thus regulating a plethora of physiological and pathological processes including cell cycle arrest in epithelial and hematopoietic…. (UniProt, P36897)

Open in Phaseline: the race on TGFBR1, likelihood bands and readouts

Programs

CompanyDrugTargetsHighest phaseConditionsNext expected readout
ImmuneOnco Biopharmaceuticals (Shanghai) Inc.IMM01 (timdarpacept)
ALK5/TGF-β receptor inhibitor
TGFBR1Phase 3Chronic Myelomonocytic LeukemiaOct 2029
Providence Health & ServicesGalunisertib (LY2157299)
TGF-beta receptor type I inhibitor
TGFBR1Phase 2Rectal AdenocarcinomaDec 2026
Sidney Kimmel Comprehensive Cancer Center at Johns HopkinsGalunisertib (LY2157299)
TGF-beta receptor type I inhibitor
TGFBR1Phase 2Prostate CancerDec 2026
The Netherlands Cancer InstituteGalunisertib
TGF-beta receptor type I inhibitor
TGFBR1Phase 1Colorectal Cancer MetastaticDec 2026
MedPactoVactosertib
TGF-beta receptor type I inhibitor
TGFBR1Phase 1Osteosarcoma; Adenocarcinoma EsophagusDec 2027
M.D. Anderson Cancer CenterTasquinimod
TGF-β receptor type I (ALK5) inhibitor
TGFBR1Phase 1Primary MyelofibrosisMay 2029

Conditions

Chronic Myelomonocytic Leukemia (1) Primary Myelofibrosis (1) Osteosarcoma (1) Adenocarcinoma Esophagus (1) Rectal Adenocarcinoma (1) Colorectal Cancer Metastatic (1) Prostate Cancer (1)

Modalities

small molecule (5), mixed (1)

Companies

ImmuneOnco Biopharmaceuticals (Shanghai) Inc. (1) M.D. Anderson Cancer Center (1) MedPacto (1) Providence Health & Services (1) The Netherlands Cancer Institute (1) Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins (1)

Related targets

–

Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.